Matches in Nanopublications for { ?s ?p "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP834547.RAvV-FQM35lmeClUgcQHqodLBmILxc9zyN7pjbahCuHwQ130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP834547.RAvV-FQM35lmeClUgcQHqodLBmILxc9zyN7pjbahCuHwQ130_provenance.
- NP713687.RAcJZgkFyf7yjVUo5BcSF7r_RehdeCf7hxWz6P9jySUWw130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP713687.RAcJZgkFyf7yjVUo5BcSF7r_RehdeCf7hxWz6P9jySUWw130_provenance.
- NP493098.RAdRBySTAJzFvP1u8_3yVY2_V3LJZNjCp-QsYfh8zi8zg130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493098.RAdRBySTAJzFvP1u8_3yVY2_V3LJZNjCp-QsYfh8zi8zg130_provenance.
- NP1404174.RAAKoSMYOUNQ_6vUB6BSmI_Qt6BnV8iOY4JaywFvOr1Kc130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404174.RAAKoSMYOUNQ_6vUB6BSmI_Qt6BnV8iOY4JaywFvOr1Kc130_provenance.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.
- NP493204.RANGJfaG8LJ8rIldAtQDRGtwyUYX6j2JAm9HKAXmTKDO8130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493204.RANGJfaG8LJ8rIldAtQDRGtwyUYX6j2JAm9HKAXmTKDO8130_provenance.